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Abstract
Background: Praziquantel remains the drug of choice for the worldwide treatment and control of schistosomiasis. The drug
is synthesized and administered as a racemate. Use of the pure active enantiomer would be desirable since the inactive
enantiomer is associated with side effects and is responsible for the extremely bitter taste of the pill.
Methodology/Principal Findings: We have identified two resolution approaches toward the production of praziquantel as a
single enantiomer. One approach starts with commercially available praziquantel and involves a hydrolysis to an
intermediate amine, which is resolved with a derivative of tartaric acid. This method was discovered through an open
collaboration on the internet. The second method, identified by a contract research organisation, employs a different
intermediate that may be resolved with tartaric acid itself.
Conclusions/Significance: Both resolution procedures identified show promise for the large-scale, economically viable
production of praziquantel as a single enantiomer for a low price. Additionally, they may be employed by laboratories for
the production of smaller amounts of enantiopure drug for research purposes that should be useful in, for example,
elucidation of the drug’s mechanism of action.
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Introduction
Schistosomiasis (bilharziosis) is termed a "neglected" tropical
disease owing to the continuing low level of investment in
treatments, prevention and research, yet the disease accounts for
an extraordinarily high level of suffering around the world.[1,2]
Schistosomiasis has been called a "silent pandemic".[3]
Over the past decades several compounds have been used for
the treatment of schistosomiasis,[4–6] but today there is only one
drug of choice, a highly effective small molecule called
praziquantel (PZQ).[7,8] PZQ is produced on a very large scale
(300 metric tons worth of API per year) and is used primarily in
veterinary medicine. In human medicine, PZQ is used essentially
as preventive (mass) chemotherapy for all forms of schistosomiasis -
whereby school-aged children or entire communities are given a
dose of PZQ once a year. Such mass treatment programs (e.g. that
coordinated by the Schistosomiasis Control Initiative)[9] deploy
100 million tablets annually, and there is expected to be a further
large growth in the demand for PZQ in the coming years.[10]
With increasing use comes an increased risk of the development
of resistance or tolerance by the parasite. Decreased drug
sensitivity was developed via an artificial selection experiment in
the laboratory,[11] and reports of similar decreases have already
been noted in the field.[12–15] Reliance on a single drug for
intensive mass treatment is risky. While there have been attempts
to find bioactive PZQ analogs,[16–18] as well as the discovery of
new compounds for the treatment of schistosomiasis based on
different modes of action,[19,20] in the short term it is sensible to
continue to use PZQ in a way that maximizes its life as a useful
drug.
PZQ is synthesized and administered as a racemate. The L-(–)-
enantiomer is the eutomer[21–24] and has the (R) configura-
tion.[7,23] Administration of the pure eutomer resulted in fewer
side effects than the racemate.[22] The inactive (+)-enantiomer is
associated with side effects and is also primarily responsible for the
extremely bitter taste of the pill;[25] factors such as taste and large
pill size contribute to there being a compliance problem with PZQ
in the affected communities.[26–27] The typical dose per pill
(40 mg kg
21, pill contains 600 mg active pharmaceutical ingredi-
ent (API)) is large. The pill is difficult to swallow for children (who
are the main target of mass chemotherapy campaigns) often
requiring tablets to be split and crushed, which brings out the
bitter taste even further. Decreasing the pill size, reducing side
effects and removing the bitter taste, while having the right
amount of the active ingredient, could be accomplished were the
drug to be made available as a single enantiomer. For these
reasons investigations into the viability of a process-scale route to
enantiopure PZQ were included in the WHO/TDR business plan
for 2008–2013.[28] Availability of the separate enantiomers would
be a valuable tool for the elucidation of the mechanism of action of
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such experiments the inactive enantiomer would act as the perfect
control.
There are typically four methods available for the conversion of
a racemic synthesis to one that generates a single enantiomer
(Figure 1): 1) Enantioselective synthesis, 2) Chromatographic
separation, 3) Stereoablation (destruction and selective reconstruc-
tion of the stereocenter) and 4) Resolution. To date, reports of the
preparation of enantiopure PZQ either have insufficient detail to
allow for their appraisal, or likely do not have the potential for the
large-scale production of the drug given the severe price
constraint;[25,30–34] for example with enantioselective chro-
matographic approaches significant quantities of solvents would be
required.
Racemic praziquantel is off-patent. Through market forces, and
its production on such a large scale, the racemate is available for
approximately US10¢ per gram. A reasonable price for wide
distribution of the enantiopure compound would therefore be
approximately US20¢ per gram since half the dose is required of
the enantiopure compound. Can enantiopure PZQ be obtained
without a significant increase in price? It is a challenge for either
academia or industry to solve this problem, for different reasons.
This article describes the discovery of two solutions, one by an
open collaborative project that starts from rac-PZQ, and one
conducted by a contract research organization that employs a
commercially-available precursor. We term these ‘‘resolutions of
praziquantel’’ for simplicity. Formally both processes involve the
resolution of a precursor or derivative that is then converted to
praziquantel.
Methods
(rac)-PZQ was a gift from WHO/TDR; the sample was
originally synthesized by Merck. Analytical samples of (R)- and
(S)-PZQ were a gift from Intervet Innovation GmbH and were
prepared according to the literature method.[25]
Hydrolysis of PZQ
HPLC Analysis of (rac)-PZQ. Enantiomeric composition of
praziquantel can be assayed by a number of enantioselective
HPLC columns. For example: Chiralcel OD-H column, hexane/
isopropanol/triethylamine solvent system (60:40:0.1), flow rate
0.7 mL per minute. Retention times: 11.6 (R-(–)-PZQ) and 13.7 (S-
(+)-PZQ) minutes.[35] (Figure S1)
HPLC Analysis of (rac)-PZQamine. Enantioselective
HPLC columns suitable for baseline separation of the enan-
tiomers of praziquanamine include Chiralcel OJ-H, Chiralpak IA
and AS-H;[36] (Text S1) eluent solvent system: heptane/EtOH/
Et2NH (60:40:0.2) at 0.5–0.7 mL/min flow rate. Columns found
to be unsuitable include Chiralcel OD,[17] OD-H, Chiralpak
IB[36] and AD-H.[37] (Figure S2).
Hydrolysis of (rac)-PZQ to (rac)-PZQamine. [38] (rac)-
PZQ (20.0 g, 64.0 mmol) was dissolved in a mixture of EtOH
(150 mL) and 1 N HCl (600 mL) and heated at reflux for 26 h.
The solution was cooled to rt and washed with ethyl acetate
(3610 mL). The ice-cooled solution was adjusted to pH 12 with 5
N NaOH and extracted with DCM (4630 mL). The combined
organic layers were washed with brine, dried over sodium sulfate
and concentrated under reduced pressure. The residual yellow
solid (12.4 g, 61.3 mmol, 96%) was recrystallized from toluene
and a further batch of analytically identical crystals was obtained
from the mother liquor after concentration and recrystallization.
PZQamine was thus obtained as a pale yellow solid (11.9 g,
58.8 mmol, 92% yield).
m.p. 117–118uC (lit.[17] 116–118uC and[39] 117–119uC).
1H
NMR (CDCl3, 200 MHz): d 1.76 (bs, 1H), 2.64–3.02 (m, 4H),
3.49 (d, J=17.6, 1H), 3.61 (d, J=17.4, 1H), 3.67 (ddd, J=13.2,
4.7, 1.2, 1H), 4.69–4.85 (m, 2 H), 7.04–7.20 (m, 4H) (Figure S3).
13C NMR (CDCl3, 50.3 MHz): d=29.4, 39.4, 50.4, 50.7, 57.5,
125.3, 127.2, 127.6, 130.0, 134.8, 135.6, 167.9. (Figure S4)
Spectroscopic data match those reported in the literature.[17,39]
Hydrolysis of (S)-PZQ. [40] To (S)-PZQ (300 mg, 960 mmol)
in EtOH (3 mL) was added 1 N HCl (12 mL) and the mixture was
heated at reflux for 18 h. The yellow solution was cooled to rt and
Figure 1. General approaches to the preparation of enantiopure praziquantel (PZQ).
doi:10.1371/journal.pntd.0001260.g001
Author Summary
The drug praziquantel (PZQ) is used very widely in both
animal and human medicine, where it is the mainstay of
the treatment of the neglected tropical disease schistoso-
miasis. The drug is currently manufactured and adminis-
tered as a racemate (1:1 mixture of enantiomers) but for
various reasons the large-scale production of PZQ as the
single active enantiomer is very desirable. We describe
here the preparation of praziquantel as a single enantio-
mer using classical resolution. The protocols are experi-
mentally simple and inexpensive. One method was found
and validated by an unusual research mechanism—open
science—where the details of the collaboration (involving
academic and industrial partners) and all research data
were available on the web as they were acquired, and
anyone could participate. The other route was found in
parallel by a contract research organisation. Besides being
possible routes by which praziquantel may be produced in
large quantities for the affected communities, it is also
hoped that these methods can be used for the production
of smaller quantities of enantiopure PZQ for pharmaco-
logical studies.
Resolution of Praziquantel
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extracted with DCM (365 mL), the combined organic layers were
washed with brine, dried over NaSO4 and concentrated under
reduced pressure. The remaining yellow solid was purified by flash
column chromatography (silica gel, ethyl acetate:methanol:
triethylamine, 4:1:0.01) to give (S)-(+)-PZQamine as a pale yellow
solid (122 mg, 63%). m.p. 117–118uC. (lit.[32] 120uC). Rf 0.23
(ethyl acetate:methanol:triethylamine, 4:1:0.01). [a]D
20=296u
(c=1, DCM) (lit.[32] [a]D
20 ((R)-(–)-PZQamine) =-306u (solvent,
concentration and temperature not specified; another source[17]
quotes (R)-PZQamine and (S)-PZQamine as [a]D
20=–152
(c=4.0610
–3,C H 2Cl2) and [a]D
20=+146 (c=3.1610
–3, DCM)
for enantiomeric excesses higher than 95 and 91%, respectively.
Relationship between Optical Purity and Optical Rotation
for PZQ[41]
To a solution of (R)-(–)-PZQ (c=1, EtOH) was added a solution
of (S)-(+)-PZQ (c=1, EtOH) to give a total volume of 1 mL (Table
S1). The results indicate a linear relationship between optical
purity and optical rotation (Figure S5).
Relationship between Optical Purity and Optical Rotation
for PZQamine[42]
To a solution of (S)-(+)-PZQamine (c=1, DCM) was added a
solution of rac-PZQamine (c=1, DCM) to give a total volume of
1 mL (Table S2). The results indicate a linear relationship between
optical purity and optical rotation (Figure S6).
Synthesis of Resolving Agents
(–)-Dibenzoyl-L-tartaric Acid. [43] A mixture of L-(+)-
tartaric acid (27.0 g, 180 mmol) and benzoyl chloride (73 mL,
630 mmol) was heated at 130uC for 4 h. The reaction mixture was
allowed to cool to rt, the pale yellow solid was filtered, washed with
cold diethyl ether (30 mL) and recrystallized from toluene
(400 mL) to give (–)-dibenzoyl-L-tartaric acid anhydride as a
colourless crystalline solid (48.3 g, 79%). The anhydride (48.3 g,
141 mmol) was dissolved in a mixture of acetone (200 mL) and
water (20 mL) and heated at reflux for 2 h. Water (200 mL) was
added and acetone was removed under reduced pressure. After
further addition of water (200 mL) the mixture was heated at
reflux for 5 min and allowed to cool to rt then cooled to 0uC and
held at that temperature for 30 min. The precipitate was filtered
and dried by lyophilization. (Alternatively, the solid could be
dissolved in ethyl acetate, dried over sodium sulfate and
concentrated under reduced pressure to give a colourless oil.)
The residue (,50 g) was recrystallized from isopropanol/hexane
(500 mL, 1:1) and the mother liquor was concentrated and
recrystallized two times from isopropanol/hexane (400 mL, 1:2
and 50 mL, 2:1) to give (–)-dibenzoyl-L-tartaric acidN2 isopropanol
as colourless spicular crystals (58.9 g, 68%).
m.p. 99–102uC (lit.[44] 95–98uC for (–)-dibenzoyl-L-tartaric
acidNH2O).
1H NMR (DMSO-d6, 200 MHz): d=1.03 (d,
J=6 Hz, 12H), 3.78 (sep, J=6 Hz, 2H), 5.88 (s, 2H), 7.57–7.64
(m, 4H), 7.70–7.74 (m, 2H), 8.00–8.04 (m, 4H), 14.00 (bs, 2H)
(Figure S7).
13C NMR (DMSO-d6, 50.3 MHz): d=25.5 (4C), 62.2
(2C), 71.6 (2C), 128.6 (2C), 129.1 (4C), 129.5 (4C), 134.2 (2C),
164.8 (2C), 167.3 (2C) (Figure S8). IR (neat): n=3465, 2975, 1730,
1237, 1098, 938, 706 cm
21. MS (ESI (–)) m/z (%): 357 (100) [M-
H]
-. HRMS (ESI (-)) Calcd. for [C18H13O8]: 357.0616, found:
357.0616. HRMS (ESI (+)) Calcd. for [C18H14O8Na
+]: 381.0581,
found: 381.0579. C24H30O10: calc. C 60.24%, H 6.32%; found: C
60.27%, H 6.33%. [a]D
20=-85.0u (c=1, EtOH) (no literature
data for N2
iPrOH compound).
(+)-Di-p-anisoyl-D-tartaric Acid. [45,46] A mixture of p-
methoxybenzoic acid (33.6 g, 253 mmol) and thionyl chloride
(82.0 g, 691 mmol, 50 mL) was stirred for 1 h at rt and heated at
reflux for a further 3 h. Thionyl chloride was removed by
distillation and the residue was concentrated under reduced
pressure. To the resulting crude p-methoxybenzoyl chloride
(2S,3S)-D(–)-tartaric acid (12.5 g, 83.0 mmol) was added and the
mixture was heated at 140uC for 1 h till a pale yellow solid was
formed. The mixture was heated at 160uC for a further 1 h. The
mixture was allowed to cool to 100uC and toluene (100 mL) was
added, the mixture was allowed to cool to rt and a further portion
of toluene (50 mL) was added. The colourless solid was filtered,
rinsed with a small amount of cold toluene and dried under
vacuum. The (+)-di-p-anisoyl-D-tartaric acid anhydride was
dissolved in a mixture of acetone (150 mL) and water (10 mL)
and heated at reflux for 2 h. After addition of water (100 mL)
acetone was evaporated and another portion of water (100 mL)
was added. The colourless precipitate was filtered and dried. To
remove the remaining p-methoxybenzoic acid the product was
heated at reflux with toluene (100 mL) for 15 min, the precipitate
was filtered while the mixture was hot and washed with hot
toluene. The procedure was repeated three further times to give
(+)-di-p-anisoyl-D-tartaric acid as a colourless solid (19.9 g, 57%).
m.p. 186–188.5uC (lit.[47] 186uC).
1H NMR (DMSO-d6, 200
MHz): d=3.50 (bs, 2H), 3.86 (s, 6H), 5.80 (s, 2H), 7.13 (d, J=8
Hz, 4H), 7.97 (d, J=8 Hz, 4H), 13.80 (bs, 2H). (Figure S9)
13C
NMR (DMSO-d6, 50.3 MHz): d=55.7 (2C), 71.2 (2C), 114.4
(4C), 120.7 (2C), 131.6 (4C), 163.8 (2C), 164.3 (2C), 167.4 (2C).
(Figure S10). IR (neat): n=2943 cm
21, 1720, 1662, 1601, 1243,
1170, 1103, 1012, 847, 762, 691. MS (ESI (+)) m/z (%): 875 (35)
[2M+K]
+, 859 (85) [2M+Na]
+, 441 (53) [M+Na]
+, 435 (85), 329
(100). HRMS (ESI (+)) Calcd. for [C20H18O10Na]
+: 441.0792,
found: 441.0790. [a]D
20=+169u (c=1, MeOH), (lit.[47]
[a]D
20=+167u (c=1, MeOH).
Resolution of PZQamine [48]
rac-Praziquanamine (10.0 g, 49.5 mmol) and (–)-dibenzoyl-L-
tartaric acidN2 i-PrOH (23.7 g, 49.5 mmol) were dissolved in
isopropanol (450 mL) and water (90 mL) by heating the stirred
mixture. The solution was allowed to cool to rt and after 2 h the
colourless crystals were filtered and dried to yield the salt as pale
yellow crystals (12.1 g, 44%). m.p. 145.5–147.5uC. Small-scale
liberation of amine (procedure below) gave [a]D
20 (liberated
amine) =-242u (c=1, DCM), implying 79% ee (determined by
polarimetry).
The salt was recrystallized from a mixture of isopropanol
(180 mL) and water (90 mL). The crystalline precipitate was kept
at 5uC for 12 h before filtration, though the crystallization is
essentially complete after 2 h. This procedure gave the salt as
colourless spicular crystals (10.2 g, 85% from this procedure, 37%
overall). m.p. 147.3–148.5uC.
Liberation of (R)-PZQamine. The salt (10.2 g, 18.3 mmol)
was suspended in water (100 mL) and the pH of the mixture was
adjusted to 11 by addition of 2 N sodium hydroxide solution.
Alternatively the salt can be dissolved in 12% aq. solution of
potassium carbonate (150 mL).[45] When the salt was completely
dissolved the solution was extracted with dichloromethane
(4615 mL). The combined organic layers were washed with
brine, dried over sodium sulfate and concentrated under reduced
pressure to give R-(–)-PZQamine as a colourless solid (3.32 g, 33%
overall). m.p. 122–123uC. [a]D
20=-305u (c=1, DCM), 99% ee
(determined by polarimetry).
Recovery of (S)-PZQamin. The combined mother liquors of
the crystallization process were concentrated under reduced
Resolution of Praziquantel
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suspension was dissolved by adding 2 N sodium hydroxide or
12% aq. solution of potassium carbonate until a pH 10–11 was
reached. The solution was extracted with dichloromethane
(4615 mL). The combined organic layers were washed with
brine, dried over sodium sulfate and concentrated under reduced
pressure to give enantioenriched S-(+)-PZQamine as a yellow solid
(5.34 g, 53%). m.p. 102–104uC. [a]D
20=+170u (c=1, DCM),
56% ee (determined by polarimetry).
Recycling of the Resolving Agent. The combined basic aq.
portions from both amine liberation processes were adjusted to
pH 2–3 by addition of 2 N aq. HCl immediately after the
extraction of PZQamine. (Allowing the aqueous portions to stand
at alkaline pH tends to result in hydrolysis of the resolving agent.)
The resulting colourless precipitate was filtered, washed with cold
water and dried under vacuum to give (–)-dibenzoyl-L-tartaric
acid as a colourless solid (21.1 g, 89%). For further purification the
solid was recrystallized from acetone/hexane (1:2).[48]
Synthesis of R-(–)-PZQ from R-(–)-PZQamine [49]
To an ice-cooled solution of R-(–)-PZQamine (3.27 g,
16.2 mmol) and triethylamine (2.45 g, 3.38 mL, 24.3 mmol,
1.5 eq.) in dichloromethane (80 mL) was added dropwise
cyclohexanoyl chloride (2.62 g, 2.39 mL, 17.8 mmol, 1.1 eq.) at
0uC and stirring was continued for 14 h at rt. The solution was
quenched with water (10 mL) and stirred for a further 30 min.
The layers were separated and the organic layer was washed with
saturated sodium carbonate solution, 0.5 N HCl solution and
brine, dried over magnesium sulfate and concentrated under
reduced pressure. The remaining yellow oil became solid after
drying under high vacuum and storing at 5uC. The pale yellow
solid was recrystallized from acetone/hexane (35 mL, 1:1 mixture)
and two further batches of analytically identical crystals were
obtained from the mother liquor after concentration and
recrystallization. R-(–)-PZQ was thus obtained as colourless
crystals (4.56 g, 90%, 97% ee). (Figure S11) m.p. 113.5–114.5uC.
[a]D
20=-136u (c=1, EtOH).
Resolution Procedure via Benzoyl Intermediate 3
An outline description of this procedure can be found
online.[50]
Results and Discussion
A coordination website was created on which was posted the
problem of the preparation of praziquantel as a single enantio-
mer.[51] While suggestions were received, input was initially low.
In mid-2008 the project was funded by a government/NGO
consortium. The resulting raw experimental data were posted in
full to an open, online electronic lab notebook (based on the open
source electronic lab notebook system, Labtrove, developed by the
University of Southampton, UK. [52]) Periodic updates were
posted on the coordination website, and the project was
popularised to increase traffic (For a description of how the open
science project was conducted, see the accompanying paper [53]).
Two approaches were begun in the laboratory that have so far
proved intractable. The first, a community suggestion, relied on
oxidation of PZQ to an enamide, which was to be subsequently
hydrogenated asymmetrically[54] (a similar approach was de-
scribed in a patent, employing Raney Nickel modified with tartaric
acid, giving products with low optical purities – see reference [34]);
this is a strong approach owing to the highly effective use of
asymmetric hydrogenation in process chemistry.[55] Through an
online collaborative process, catalysts are being screened for this
reduction[56] but the reaction is difficult owing to the lack of a
well-placed coordinating group able to direct the metal catalyst to
the double bond. The second approach was based on an
asymmetric Pictet-Spengler reaction.[57] Catalysts for similar
reactions are known,[58] and the relevant starting material (a
peptide acetal) is an intermediate in two known syntheses of
PZQ.[39,59] Unfortunately this substrate contains an unreactive
aromatic ring (i.e. lacking electron donating groups), and at the
time of writing no known asymmetric catalyst has given conversion
to PZQ.
The third possibility was resolution. Such an approach is widely
used in the process-scale production of enantioenriched interme-
diates because the relevant chiral resolving agents are frequently
inexpensive and/or can be recycled. Inputs to the collaborative
website and elsewhere suggested this approach was more likely to
lead to an economically viable solution to the problem.[60] In
response, this approach was prioritized.
To effect a resolution, PZQ should be hydrolysed to
praziquanamine (PZQamine, Figure 2A). The process must
employ only crystallizations (rather than chromatography) to be
practicable. The use of procedures that avoid the synthesis of
complex catalysts, chromatographic purifications and NMR-based
assessments of purity would also assist laboratories in underdevel-
oped countries to access enantiopure PZQ locally on smaller
scales.
In the corresponding author’s laboratory, PZQamine could be
generated with ease, but the enantiomers could not be baseline
separated by enantioselective HPLC due to a limited range of
chiral stationary phases being available. This precluded a
convenient local assay for resolution trials. In addition several
attempts to resolve PZQamine with a range of chiral acids had met
with mixed success.[61–62] To find a suitable chromatographic
assay, an appeal for assistance was posted in several online
discussion boards. In particular, the Process Chemists Group on
LinkedIn furnished multiple offers of help. One company, Syncom
B.V., a contract research organization in the Netherlands,
additionally offered to perform a free screen of chiral acids for
the resolution of PZQamine in order to discover a lead structure
for the project. One gram of racemic PZQamine was shipped to
Syncom. An effective chiral stationary phase was found,[36]
followed by a chiral resolving agent ((–)-di-p-anisoyl-L-tartaric
acid) that permitted the isolation of the desired (R)-enantiomer of
PZQamine from the mother liquor in ca. 66% ee, which could be
increased to 95% ee after one recrystallization.[63]
With this lead in hand, optimization of the process was carried
out. The resolving agent in question is commercially available
(reasonably expensiveon a small scale) but could be synthesised from
tartaric acid. However, purification away from the p-methoxyben-
zoic acid byproduct formed during its synthesis was non-trivial. It
was also thought that isolation of the desired enantiomer of
PZQamine from the resolved solid, rather than the mother liquor,
would be more desirable; hence (+)-di-p-anisoyl-D-tartaric acid was
prepared[46] and used for the resolution of praziquanamine to give
the desired (R)-(–)-praziquanamine in the first-precipitated salt.[64]
Such an approach is sub-optimal since this resolving agent must be
obtained from unnatural enantiomer of tartaric acid. It was found
that the simple expedient of using (–)-dibenzoyl-L-tartaric acid solved
both these problems, allowing the isolation of (R)-PZQamine in 44%
yield and 80% ee without recrystallization and 33% yield and 97% ee
after one recrystallization (the maximum yield for a resolution is
50%). Although we did not expect (–)-dibenzoyl-L-tartaric acid and
(–)-di-p-anisoyl-L-tartaric acid to give opposite enantiomers of
praziquanamine in the first-precipitated salts based on our
experience with Dutch resolution and the ‘‘family’’ behaviour of
Resolution of Praziquantel
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behaviour has been observed in other resolutions.[65–66] No
Horeau effect[67] is observed for either PZQ[41] or PZQamine[42]
in common solvents and concentrations at room temperature,
meaning that for analytically pure samples of either, optical activity
can be used as an assessment of optical purity in laboratories without
access to enantioselective HPLC.
(R)-PZQamine can be converted to (R)-PZQ with commercially-
available cyclohexanoyl chloride in 90% yield,[49] thus complet-
ing the formal resolution of PZQ. The resolving agent can be
recycled in 89% yield. Conditions to effect the racemization of the
undesired (+)-PZQamine are now being sought.[68]
At the same time as this procedure was being discovered by an
open approach, another contract research organisation was asked
(byWHO/TDR)to lookintosolutions to the same problemwithout
communication to the open project. This led to the discovery of a
complementary resolution (Figure 2B). From an investigation of
compounds available in bulk, a resolution of a commercially-
availableintermediate(3)wasassayed.Tartaricacid couldeffectthis
resolutionto provide the enantioenrichedintermediate in 37% yield
and 94% ee. PZQ could be synthesized from enantioenriched 3 by
cyclization with chloroacetyl chloride and removal of the benzoyl
group, generating (R)-PZQamine, which can be taken on to provide
enantiopure (R)-PZQ as before. A summary of this method was
posted to the coordination website when complete.[50]
Full experimental details for the open process may be found in
this paper. Readers are encouraged to review, evaluate and
contribute to refining the resolutions online by addressing current
weaknesses (e.g., the need for a chlorinated solvent extraction
process in the initial PZQ hydrolysis). Both processes show sufficient
promise in terms of cost on a lab scale (simple methodology,
inexpensive resolving agents, good yields and efficiencies) that costs
approaching those needed should be attainable upon scale-up; the
processes are therefore being examined by WHO/TDR on a
kilogram scale for economic viability. The routes found are quite
similar. An advantage of the approach discovered by the CRO is its
use of tartaric acid itself, as opposed to a derivative, but the
derivatization employed in the open approach is straightforward.
Which route is adopted depends to some extent on the method(s)
currently employed in the commercial manufacture of the API, and
perhaps surprisingly this information is not readily available. The
ton-scale availability of 3 implies its use in the synthesis of PZQ,
presumably via the original Merck process,[7] yet to the best of our
knowledge the CRO manufacturing PZQ for the Schistosomiasis
Control Initiative (Shin Poong, South Korea) were employing a
different approach[39] that generated PZQamine 2 as an
intermediate, implying a similar availability of that material in
quantity. The open source approach is the basis of an educational
project in which students from around the world are encouraged to
collaborate in further optimization. (Interested students and
laboratory instructors can view the experiments and collaborate
on the relevant website[69]).
It is clear that the availability of a new synthetic route, even if it
is economically viable, does not translate automatically into a
product available to the end-user. Additional elements must be
taken into consideration including the regulatory requirements for
further studies (chemistry, manufacturing & control; non-clinical;
and clinical). While the time and costs associated with this process
are expected to be significantly less than with a typical new
chemical entity, they are yet to be quantified and supported.
WHO/TDR is actively seeking commercial partners potentially
interested in pursuing this project as well as sources of funding.
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